- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01429467
Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation (INDIGO 2)
Improving Glucose Variability in Type 1 Diabetes and Its Effect on the Underlying Homeostatic Metabolic Pathways of Angiogenesis
Study Overview
Status
Conditions
Detailed Description
The study will have two parts. The first phase will look at all current paediatric type 1 diabetics in Tayside on continuous subcutaneous insulin pump therapy and measure their levels of Hypoxia-Inducible Factor (HIF), Vascular Endothelial Growth Factor (VEGF), erythropoietin and cortisol. This will help answer the question; Does glucose control (as expressed by HbA1c ) effect levels of HIF, VEGF, erythropoietin and cortisol? To our knowledge this will be the first human study comparing how HIF, VEGF, erythropoietin and cortisol are affected by glucose control
The second phase of the trial will chose 10 patients on insulin pump therapy and using a continuous glucose monitor (CGM), monitor their glucose variability over a period of 6 weeks. After this period their levels of HIF, VEGF, erythropoietin and cortisol will again be measured. This will help answer the question of whether there is a relationship between glucose variability and levels of HIF, VEGF, erythropoietin and cortisol. As we know that these factors are stimulated by episodes of hypo and hyperglycaemia, it is hypothesised that these factors will be lower in participants that demonstrate reduced glucose variability. It will be the first study to give detailed information on the relationship between HIF, VEGF, erythropoietin and cortisol and glucose variability.
By using telemedicine sessions during weeks 1, 3 and 5 of the participants wearing CGM we will aim to improve the participant's glucose variability. This will help give further information about glucose variability and the above factors as well as giving further evidence for the use of telemedicine and CGM to improve glycaemic control in adolescent diabetics.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Angus
-
Dundee, Angus, United Kingdom, DD1 9SY
- University of Dundee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Phase 1 inclusion:
- Patients with Type 1 Diabetes
- On insulin pump therapy.
- Aged 5 years to 18 years.
Phase 2 inclusion:
- Patents with Type 1 Diabetes
- Diabetes diagnosis for 1 year
- On insulin pump therapy for minimum of six months
- Access to a computer with internet access and telephone
- Agree to wear CGM for 6 weeks
- Aged 12 years to 18 years
Exclusion Criteria:
- Patients not on pump therapy
- Patient less than 5 years and greater than 18 years
- Phase 2 patients been on pump therapy for less than 6 months
- Phase 2 patients without access to internet and telephone.
- Phase 2 patients less than 12 years and greater than 18 years
- Patients who do not have a good understanding of English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Continuous Glucose Monitoring (CGM)
10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5.
After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
|
Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®).
Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate.
This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010).
Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of HbA1c and level of Hypoxia-inducible Factor
Time Frame: Baseline
|
This will look at all the results from Phase 1 participants and see if their is a correlation between participants HbA1c and their level of Hypoxia-inducible factor.
|
Baseline
|
Correlation of HbA1c and level of Vascular Endothelial Growth Factor
Time Frame: Baseline
|
This will look at all the results from Phase 1 participants and see if their is a correlation between participants HbA1c and their level of Vascular Endothelial Growth Factor.
|
Baseline
|
Correlation of HbA1c and level of Erythropoietin
Time Frame: Baseline
|
This will look at all the results from Phase 1 participants and see if their is a correlation between participants HbA1c and their level of Erythropoietin.
|
Baseline
|
Correlation of HbA1c and level of cortisol
Time Frame: Baseline
|
This will look at all the results from Phase 1 participants and see if their is a correlation between participants HbA1c and their level of Cortisol.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mean Area of Glucose Excursion (MAGE) following CGM
Time Frame: 6 weeks
|
The Mean Area of Glucose Excursion (MAGE) will be calculated for all phase 2 particpants from the CGM data in the first 3 days and last 3 days of the 6 week CGM period.
These will then be compared to see if there is a statistical difference between MAGE after CGM intervention.
|
6 weeks
|
Change in levels of Hypoxia-inducible factor following CGM
Time Frame: 6 weeks
|
Levels of Hypoxia-inducible factor will be measured in phase 2 participants post CGM and compared with baseline Hypoxia-inducible factor taken in phase 1 to see if there is a statistical difference.
|
6 weeks
|
Change in levels of Vascular Endothelial Growth Factor following CGM
Time Frame: 6 weeks
|
Levels of Vascular Endothelial Growth Factor will be measured in phase 2 participants post CGM and compared with baseline Vascular Endothelial Growth Factor taken in phase 1 to see if there is a statistical difference.
|
6 weeks
|
Change in levels of erythropoietin following CGM
Time Frame: 6 weeks
|
Levels of Erythropoietin will be measured in phase 2 participants post CGM and compared with baseline Erythropoietin taken in phase 1 to see if there is a statistical difference.
|
6 weeks
|
Change in levels of cortisol following CGM
Time Frame: 6 weeks
|
Levels of Cortisol will be measured in phase 2 participants post CGM and compared with baseline Cortisol taken in phase 1 to see if there is a statistical difference.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony PB Tasker, MBChB, University of Dundee
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT/V01/010911
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesRecruiting
Clinical Trials on Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)
-
Becton, Dickinson and CompanyCompleted
-
Jaeb Center for Health ResearchJDRF Artificial Pancreas ProjectCompletedType 1 DiabetesUnited States
-
Amsterdam UMC, location VUmcEli Lilly and CompanyCompletedType 1 Diabetes Mellitus | Hypoglycemia UnawarenessNetherlands
-
M.D. Anderson Cancer CenterMedtronicTerminated
-
Norwegian University of Science and TechnologyNorwegian Diabetes AssociationCompletedDiabetes Mellitus, Type 1Norway
-
Charles University, Czech RepublicUnknown
-
Sheba Medical CenterUnknownDiabetes MellitusIsrael
-
Vanderbilt University Medical CenterRecruitingDuchenne Muscular DystrophyUnited States
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Novo... and other collaboratorsCompletedType1 Diabetes MellitusUnited States
-
Vanderbilt University Medical CenterActive, not recruitingDuchenne Muscular DystrophyUnited States